Saniona AB (publ) (SANION.ST)

SEK 8.05

(3.34%)

Market Cap (In SEK)

900.67 Million

Revenue (In SEK)

16.84 Million

Net Income (In SEK)

-95.81 Million

Avg. Volume

593.24 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.736-8.24
PE
-
EPS
-
Beta Value
0.968
ISIN
SE0005794617
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jorgen Drejer Ph.D.
Employee Count
-
Website
https://www.saniona.com
Ipo Date
2014-04-22
Details
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.